Soleno Therapeutics, Inc. (SLNO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

57.78

+3.15

(+5.77%)

At close: 04:00PM EST

57.00

-0.78

(-1.35%)

After hours:

04:51PM EST

Trade prices are not sourced from all markets

All

GlobeNewswire
Soleno Therapeutics Announces Oral Presentations featuring Diazoxide Choline Extended-Release (DCCR) Tablets in Prader-Willi Syndrome at ESPE 2024
REDWOOD CITY, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will be presenting data from its DCCR clinical development program for the treatment of Prader-Willi syndrome (PWS) at the 62nd Annual European Society for Paediatric Endocrinology (ESPE) Meeting 2024, being held November 16-18, 2024 in Liverpool, UK. Detail
Simply Wall St.
Here's Why We're Not At All Concerned With Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...